SAB BIOTHERAPEUTICS INC (SABS) Stock Analyst Earnings Estimates
NASDAQ:SABS - Nasdaq - US78397T2024 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 60.876M 10.21% | 23.904M -60.73% | 2.239M -90.63% | 1.351M -39.66% | 1.02M -24.50% | 1.275M 25.00% | 892.5K -30.00% | 1.02M 14.29% | 71.955M 6,954.41% | 313.14M 335.19% | |
| EBITDA YoY % growth | -11.905M -156.85% | -25.627M -115.26% | -34.322M -33.93% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -13.394M -165.16% | -28.796M -114.99% | -37.975M -31.88% | -45.185M -18.99% | -50.376M -11.49% | -58.232M -15.60% | -72.197M -23.98% | -83.354M -15.45% | -74.131M 11.06% | 24.361M 132.86% | |
| Operating Margin | -22.00% | -120.47% | -1,696.07% | -3,344.58% | -4,938.78% | -4,567.22% | -8,089.29% | -8,171.97% | -103.02% | 7.78% | |
| EPS YoY % growth | N/A | -2.70 -37.51% | -7.28 -169.63% | -3.75 48.44% | -3.03 19.36% | -2.69 11.04% | N/A | N/A | N/A | N/A |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.19 64.92% | -0.73 -22.40% | -0.63 20.59% | -0.61 45.36% | -0.61 48.39% | -0.84 -13.89% | -0.87 -38.21% | -0.90 -46.67% | -0.93 -51.67% |
| Revenue Q2Q % growth | 153K -49.84% | 510K -45.97% | 510K 93.92% | 510K | 510K 233.33% | 510K | 510K | 510K | 510K |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -11.705M 37.98% | -11.373M 0.16% | -11.985M -18.30% | -12.291M -9.36% | -12.903M -10.24% | -13.77M -21.08% | -14.382M -20.00% | -14.994M -21.99% | -15.606M -20.95% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -1.12 -12.00% | -1.11 | -0.01 | -0.74% |
| Q2 2024 Q2Q % growth | -0.79 43.57% | -1.15 | 0.36 | 31.46% |
| Q1 2024 Q2Q % growth | -0.60 60.00% | -0.98 | 0.38 | 38.73% |
| Q4 2023 Q2Q % growth | -3.38 -1,590.00% | -0.63 | -2.75 | -434.47% |
| Q3 2023 Q2Q % growth | -1.00 37.50% | -1.19 | 0.19 | 15.97% |
| Q2 2023 Q2Q % growth | -1.40 -27.27% | -1.48 | 0.08 | 5.34% |
| Q1 2023 Q2Q % growth | -1.50 -850.00% | -0.82 | -0.68 | -83.82% |
| Q4 2022 Q2Q % growth | -0.20 96.97% | -0.36 | 0.16 | 43.98% |
| Q3 2022 Q2Q % growth | -1.60 -700.00% | -1.63 | 0.03 | 1.96% |
| Q2 2022 Q2Q % growth | -1.10 | -1.73 | 0.63 | 36.56% |
| Q1 2022 Q2Q % growth | 0.20 | -1.68 | 1.88 | 111.88% |
| Q4 2021 Q2Q % growth | -6.60 | -1.12 | -5.48 | -488.24% |
| Q3 2021 Q2Q % growth | -0.20 | -0.88 | 0.68 | 77.38% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -100.00% | 153K | -153K | -100.00% |
| Q2 2024 Q2Q % growth | 263K 207.53% | 263K | % | |
| Q1 2024 Q2Q % growth | 944K 62.45% | 944K | % | |
| Q4 2023 Q2Q % growth | 305K -85.89% | 305K | % | |
| Q3 2023 Q2Q % growth | 1.267M -64.71% | 20.4K | 1.247M | 6,110.78% |
| Q2 2023 Q2Q % growth | 85.52K -98.65% | 414.803K | -329.283K | -79.38% |
| Q1 2023 Q2Q % growth | 581.1K -95.08% | 2.406M | -1.825M | -75.85% |
| Q4 2022 Q2Q % growth | 2.161M -96.45% | 6.634M | -4.473M | -67.43% |
| Q3 2022 Q2Q % growth | 3.59M | 6.987M | -3.397M | -48.62% |
| Q2 2022 Q2Q % growth | 6.351M | 11.016M | -4.665M | -42.35% |
| Q1 2022 Q2Q % growth | 11.803M | 11.696M | 107K | 0.91% |
| Q4 2021 Q2Q % growth | 60.876M | 15.3M | 45.576M | 297.88% |
| Q3 2021 Q2Q % growth | 17.238M | -17.238M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 6.25% | 0% | -3.56% |
| Revenue | 0% | N/A | 0% | -13.89% |